NCT01603277View on ClinicalTrials.gov

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

PHASE2CompletedINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

January 31, 2014

Conditions

Moderate-to-Severe Asthma

Interventions

BIOLOGICAL

Anti-GM-CSF Monoclonal Antibody 400mg

Anti-GM-CSF Monoclonal Antibody 400mg

OTHER

Placebo

Normal Saline

Trial Locations (70)

3050

Melbourne

3128

Box Hill

3199

Frankston

4102

Woolonggabba

4870

Cairns

5011

Woodville

5042

Bedford Park

6009

Nedlands

13015

Marseille

21029

Vinnytsia

27157

Winston-Salem

29407

Charleston

29425

Charleston

29615

Greenville

30046

Lawrenceville

30096

Duluth

31405

Savannah

32789

Winter Park

33136

Miami

33171

Miami

33613

Tampa

34295

Montpellier

35033

Rennes

35216

Birmingham

37044

Tours

40536

Lexington

48109

Ann Arbor

49074

Dnipropetrovsk

53226

Milwaukee

61124

Kharkiv

63110

St Louis

65009

Odesa

67091

Strasbourg

69035

Zaporizhzhya

73120

Oklahoma City

73131

Oklahoma City

76012

Arlington

77479

Sugarland

80112

Centennial

80206

Denver

80907

Colorado Springs

83099

Donetsk

89502

Reno

90025

Los Angeles

91344

Granada Hills

92270

Rancho Mirage

92835

Fullerton

95043

Simferopol

95117

San Jose

95819

Sacramento

98600

Yalta

06708

Waterbury

07901

Summit

02886

Warwick

15-010

Bialystok

05-321

Mrozy

05-200

Wiłomin

96-230

Biała Rawska

85-079

Bydgoszcz

31-033

Krakow

31-159

Krakow

90-153

Lodz

20-089

Lublin

15-044

Piasta

03680

Kyiv

ML2 0DP

Wishaw

HA6 2RN

Northwood

BD9 6RJ

Bradford

LS9 7TF

Leeds

SO16 6YD

Southampton

Sponsors

Lead Sponsor

Humanigen, Inc.

All Listed Sponsors

lead

Humanigen, Inc.

INDUSTRY